Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 42.60% is 17% below its 5-year average of 51.47%, near the low end of its 5-year range (36.87%–64.41%).
1.18% below its 12-month average of 43.11%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 38.52%.
GROSS MARGIN
42.60%
GROSS MARGIN AVG TTM
43.11%
GROSS MARGIN AVG 3Y
52.63%
GROSS MARGIN AVG 5Y
51.47%
GROSS MARGIN AVG 10Y
49.61%
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-1.18%
CURRENT VS 3Y AVG
-19.06%
CURRENT VS 5Y AVG
-17.24%
CURRENT VS 10Y AVG
-14.14%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+2.95%
vs the sector median at left
Quanterix Corporation
Market Cap
$162.28M
Gross Margin
42.60%
TTM Avg
43.11%
3Y Avg
52.63%
5Y Avg
51.47%
Market Cap
$162.23M
Gross Margin
63.55%
TTM Avg
56.95%
3Y Avg
54.72%
5Y Avg
65.55%
Market Cap
$160.65M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$165.88M
Gross Margin
63.30%
TTM Avg
63.88%
3Y Avg
62.53%
5Y Avg
60.65%
Market Cap
$166.54M
Gross Margin
99.69%
TTM Avg
100.00%
3Y Avg
-73.48%
5Y Avg
-190.92%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quanterix Corporation (QTRX) | $162.28M | 42.60% | 43.11% | 52.63% | 51.47% |
| Coherus Oncology, Inc. (CHRS)vs › | $162.23M | 63.55% | 56.95% | 54.72% | 65.55% |
| Minerva Neurosciences, Inc. (NERV)vs › | $160.65M | 0.00% | 0.00% | 0.00% | 16.67% |
| PepGen Inc. (PEPG)vs › | $159.44M | 0.00% | 0.00% | 0.00% | 0.00% |
| Nkarta, Inc. (NKTX)vs › | $165.27M | 0.00% | 0.00% | 0.00% | 0.00% |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | 85.91% | 84.21% | 85.09% | 82.87% |
| OptimizeRx Corp. (OPRX)vs › | $165.88M | 63.30% | 63.88% | 62.53% | 60.65% |
| Cue Biopharma, Inc. (CUE)vs › | $166.54M | 99.69% | 100.00% | -73.48% | -190.92% |
| Inogen, Inc. (INGN)vs › | $156.63M | 48.89% | 46.84% | 43.63% | 44.77% |
| MediWound Ltd. (MDWD)vs › | $168.86M | 15.46% | 16.11% | 25.27% | 28.77% |
Gross Margin
42.6%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 38.52% |
| 2026-03-31 | 42.75% |
| 2025-12-31 | 45.51% |
| 2025-09-30 | 42.65% |
| 2025-06-30 | 46.12% |
| 2025-03-31 | 54.03% |
| 2024-12-31 | 61.91% |
| 2024-09-30 | 55.78% |
| 2024-06-30 | 64.41% |
| 2024-03-31 | 57.48% |
| 2023-12-31 | 52.72% |
| 2023-09-30 | 60.88% |
| 2023-06-30 | 61.48% |
| 2023-03-31 | 59.16% |
| 2022-12-31 | 48.33% |
| 2022-09-30 | 40.44% |
| 2022-06-30 | 36.87% |
| 2022-03-31 | 49.27% |
| 2021-12-31 | 54.60% |
| 2021-09-30 | 53.35% |
| 2021-06-30 | 54.68% |
| 2021-03-31 | 60.09% |
| 2020-12-31 | 60.36% |
| 2020-09-30 | 65.10% |
| 2020-06-30 | 39.70% |
| 2020-03-31 | 43.32% |
| 2019-12-31 | 43.13% |
| 2019-09-30 | 47.06% |
| 2019-06-30 | 51.20% |
| 2019-03-31 | 48.69% |
| 2018-12-31 | 48.21% |
| 2018-09-30 | 52.83% |
| 2018-06-30 | 45.97% |
| 2018-03-31 | 13.26% |
| 2017-12-31 | 43.72% |
| 2017-09-30 | 44.73% |
| 2017-06-30 | 41.84% |
| 2017-03-31 | 44.21% |
| 2016-12-31 | 53.72% |
| 2016-09-30 | 38.89% |
| 2016-06-30 | 30.84% |
| 2016-03-31 | 43.72% |
